Transvaginal Mesh

Part of the debate – in the Scottish Parliament on 26th June 2019.

Alert me about debates like this

Photo of Jeane Freeman Jeane Freeman Scottish National Party

I have already mentioned the work that is under way to estimate the numbers that we might be dealing with. Our data is not as good as we want it to be, primarily because such a level of data on procedures is not routinely gathered, and we do not yet have the individual product identifier on which we are working with the MHRA. The credit for the fact that the MHRA is working on that should largely go to us for pursuing issues in relation to the way in which it approaches its work.

In relation to whether an individual can benefit from the treatment that Dr Veronikis offers here in Scotland or elsewhere, the discussions that will take place in advance of his coming to Scotland—as I said, I hope that he will be here by the autumn—will be about how he will undertake the clinical assessments, how he will access patient records and so on. We need the regulatory process to be put in place to ensure that he is properly registered to carry out that work and to access that information.

We have not discussed with Dr Veronikis the possibility of patients travelling to the US, but my answer to a previous question remains the same: that is a matter for individual clinical decisions but, should clinicians think that it was required within the timeframe and in advance, we would certainly look at that. I am sure that David Stewart understands that I will not discuss individual cases in the chamber.